Article content material
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Firm”), a commercial-stage medical machine firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 monetary outcomes after market shut on Thursday, Could 9, 2024.
Profound administration will host a convention name at 4:30 p.m. ET to overview the monetary outcomes and focus on enterprise developments within the interval.
Article content material
First Quarter 2024 Outcomes Convention Name Particulars:
| Date: | Thursday, Could 9, 2024 |
| Time: | 4:30 p.m. ET |
Stay Name Registration: https://register.vevent.com/register/BI477e53fa85fe419682e13b58f27341b0
The decision can even be broadcast dwell and archived on the Firm’s web site at www.profoundmedical.com below “Webcasts” within the Traders part.
About Profound Medical Corp.
Profound is a commercial-stage medical machine firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a expertise that mixes real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature suggestions management. TULSA-PRO® is designed to offer customizable and predictable radiation-free ablation of a surgeon-defined prostate quantity whereas actively defending the urethra and rectum to assist protect the affected person’s pure practical skills. TULSA-PRO® has the potential to be a versatile expertise in customizable prostate ablation, together with intermediate stage most cancers, localized radio-recurrent most cancers, retention and hematuria palliation in domestically superior prostate most cancers, and the transition zone in massive quantity benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Well being Canada accredited, and 510(ok) cleared by the U.S. Meals and Drug Administration (“FDA”).
Article content material
Profound can be commercializing Sonalleve®, an revolutionary therapeutic platform that’s CE marked for the remedy of uterine fibroids and palliative ache remedy of bone metastases. Sonalleve® has additionally been accredited by the China Nationwide Medical Merchandise Administration for the non-invasive remedy of uterine fibroids and has FDA approval below a Humanitarian Gadget Exemption for the remedy of osteoid osteoma. The Firm is within the early levels of exploring extra potential remedy markets for Sonalleve® the place the expertise has been proven to have scientific utility, corresponding to non-invasive ablation of belly cancers and hyperthermia for most cancers remedy.
For additional info, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Share this text in your social community
